オプションチェーンは、Soligenixの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Soligenixの市場センチメントを評価します。.

Soligenix (NASDAQ:SNGX) 株価情報, オプションチェーン

Soligenix

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix Inc

General

SNGX

Soligenix shares are trading higher after the company announced interim data from its investigator-initiated study of HyBryte for early-stage cutaneous T-cell lymphoma, which showed over 70% of patients who completed at least 18 weeks of therapy achieved "Treatment Success."

News

Market-Moving Exclusives

Exclusives

EXCLUSIVE: Soligenix Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success'

EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'

On Tuesday, Soligenix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL), a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection.
Cutaneous T-cell lymphoma&nbsp;is a group&nbsp;of rare blood cancers&nbsp;that affects the skin.
Nine patients have been enrolled and treated with HyBryte over up to 54 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41968331/soligenix-kickstarts-dusquetide-mid-stage-study-for-patients-with-inflamed-blood-vessels" rel="noreferrer noopener">Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels</a>
Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success."
Treatment Success is predefined in the study's protocol as a greater than or equal to 50% improvement in the cumulative mCAILS (modified Composite Assessment of Index Lesion Severity) score compared to the baseline.
Three of the five Treatment Successes were achieved within the first 12 weeks of treatment, with two patients achieving a "complete response" by 18 weeks.
Of the remaining patients, two have recently started the study, and two had to drop out for logistical reasons. One showed a substantial improvement (&gt;30%) by their Week 18 visit. In addition, HyBryte appears to be safe and well-tolerated in all patients.
In December, Soligenix announced that patient enrollment had opened for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for CTCL.
The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent comparative study (HPN-CTCL-04) and an ongoing investigator-initiated study, each further supporting the design of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42505309/exclusive-soligenix-starts-confirmatory-late-stage-trial-for-hybryte-for-type-of-blood-cancer" rel="noreferrer noopener">the FLASH2 clinical trial</a>.
The active ingredient in HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later.
Price Action: SNGX stock closed at $3.13 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say" target="_blank" rel="noreferrer noopener">Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts</a></li>
</ul>

Biotech

Health Care

EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year

EXCLUSIVE: Soligenix Tells Benzinga HyBryte Expanded Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma

On Monday, Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL).
The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent comparative study (HPN-CTCL-04) and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41968331/soligenix-kickstarts-dusquetide-mid-stage-study-for-patients-with-inflamed-blood-vessels" rel="noreferrer noopener">Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels</a>
The FLASH2 study is expected to enroll patients in the U.S. and Europe, and a formal interim analysis is anticipated early in 2026.
The company looks forward to providing periodic updates on the trial's progress in 2025
FLASH2 will enroll approximately 80 subjects with early-stage CTCL, a group of rare blood cancers that affect the skin.
The study replicates the double-blind, placebo-controlled design used in the first Phase 3 FLASH study, which consisted of three 6-week treatment cycles (18 weeks total). The primary efficacy assessment occurred at the end of the initial 6-week cycle (Cycle 1).
However, this second study extends to 18 weeks of continuous treatment (no "between-cycle" treatment breaks), with the primary endpoint assessment occurring at the end of the 18-week timepoint.
In the first Phase 3 study, a treatment response of 49% (p&lt;0.0001 vs patients receiving placebo in Cycle 1) was observed in patients completing 18 weeks (3 cycles) of therapy.
The extended treatment for a continuous 18 weeks in a single cycle is expected to statistically demonstrate the effect of HyBryte over a more prolonged, "real world" treatment course.
In July, Soligenix shared an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte treatment for up to 12 months in patients with <a href="https://www.benzinga.com/general/biotech/24/07/39692597/nano-cap-soligenix-stock-surges-over-200-on-tuesday-heres-why" target="_blank" rel="noreferrer noopener">early-stage CTCL</a>.
Price Action: SNGX stock closed at $3.14 on Friday.

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma

Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual Lesions Even After Stopping Treatment

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

On Thursday, Soligenix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 (dusquetide) for Behçet's Disease, an inflammatory disorder of the blood vessels (vasculitis).
The company looks forward to completing enrollment and announcing study results in the first half of 2025.
The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate Behçet's Disease and active oral and/or genital ulcers.
Patients will receive SGX945 as a twice-weekly 4-minute intravenous (IV) infusion for 4 weeks, followed by 4 weeks of follow-up.
Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance, and patient reported quality of life assessments.&nbsp;&nbsp;
Dusquetide, the active ingredient in SGX945 (Behçet's Disease) and <a target="_blank" href="https://www.soligenix.com/pipeline-programs/sgx942-treatment-for-oral-mucositis/" rel="noreferrer noopener">SGX942 (oral mucositis)</a>, is an innate defense regulator (IDR), a new class of short, synthetic peptides.
Dusquetide has demonstrated safety and tolerability in a Phase 1 study in 84 healthy human volunteers.
In Phase 2 and 3 clinical studies with dusquetide in over 350 subjects with oral mucositis due to chemoradiation therapy for head and neck cancer, positive efficacy results were demonstrated, including potential long-term <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470438/" rel="noreferrer noopener">ancillary benefits</a>.
There are approximately 18,000 known cases of Behçet's Disease in the U.S., 350,000 in Turkey, and over 50,000 in Europe. There are as many as 1 million people worldwide living with Behçet's Disease.
In July, The Princeton, New Jersey-based company announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended Hybryte treatment for up to 12 months in patients with early-stage cutaneous&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39692597/nano-cap-soligenix-stock-surges-over-200-on-tuesday-heres-why" rel="noreferrer noopener">T-cell lymphoma (CTCL)</a>.
Patients have responded positively to HyBryte therapy. Three of the four subjects who have completed at least 12 weeks of therapy already achieved "Treatment Success."
Price Action: At the last check on Thursday, SNGX stock traded higher by 1.10% to $3.67 premarket.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41950702/boeing-reportedly-plans-furloughs-whats-going-on" target="_blank" rel="noreferrer noopener">Boeing Reportedly Plans Furloughs: What's Going On</a></li>
</ul>

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

Soligenix Initiates A Phase 2 Clinical Trial Of SGX945 For The Treatment Of Behçet's Disease; Says Study DUS-AUBD-01 Opens Patient Enrollment

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 106.6% to $2.81 during Friday's after-market session. The company's market cap stands at $5.2 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares rose 8.36% to $3.37. The company's market cap stands at $114.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock moved upwards by 6.25% to $1.02. The company's market cap stands at $6.0 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock increased by 6.18% to $3.26. The market value of their outstanding shares is at $2.4 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock increased by 5.45% to $1.16. The market value of their outstanding shares is at $63.9 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock moved upwards by 5.0% to $0.39. The market value of their outstanding shares is at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 10.1% to $0.06 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 10.07% to $0.39. The market value of their outstanding shares is at $2.8 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 6.96% to $3.56. The company's market cap stands at $8.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock declined by 6.67% to $2.38. The market value of their outstanding shares is at $46.9 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares declined by 6.11% to $2.77. The market value of their outstanding shares is at $7.7 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock decreased by 5.13% to $1.85. The company's market cap stands at $45.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMRA

Envoy Medical, Inc. - Class A Common Stock

COCH

FRES

KDLY

NUWE

OMGA

PPBT

SINT

VCNX

VERO

12 Health Care Stocks Moving In Friday's After-Market Session

Soligenix Says Hong Kong Patent Office Has Granted Patent Entitled 'Systems And Methods For Producing Synthetic Hypericin'

<h3>Gainers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares increased by 17.4% to $0.82 during Monday's after-market session. The company's market cap stands at $25.3 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares rose 5.92% to $0.42. The market value of their outstanding shares is at $3.6 million. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares increased by 5.91% to $46.55. The company's market cap stands at $5.5 billion. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 5.83% to $0.26. The company's market cap stands at $1.6 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares increased by 5.22% to $1.41. The company's market cap stands at $60.1 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) stock increased by 4.97% to $13.07. The market value of their outstanding shares is at $784.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 8.7% to $0.12 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock declined by 7.6% to $2.31. The company's market cap stands at $1.9 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 6.62% to $3.95. The market value of their outstanding shares is at $9.0 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock declined by 6.39% to $0.25. The market value of their outstanding shares is at $5.5 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.43% to $1.22. The market value of their outstanding shares is at $15.6 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 5.42% to $1.31. The market value of their outstanding shares is at $78.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IMNM

KAPA

LGMK

MYNZ

OGEN

TIVC

TRVN

VINC

VRCA

12 Health Care Stocks Moving In Monday's After-Market Session

Macro Notification

GOVX

HHS Says CDC To Issue Level 3 Travel Health Notice For Rwanda On Oct 7; Rwanda Has Reported 49 Cases And 12 Deaths From Marburg Virus As Of Oct 6; CDC To Begin Public Health Entry Screening For Travelers Entering US From Rwanda Starting Week Of Oct 14; Level 3 Notice Recommends Reconsideration Of Nonessential Travel To Rwanda

Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,&nbsp;announced today that&nbsp;two of its lead investigators are presenting findings from recent additional, supportive trials with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4270389-1&amp;h=1804281992&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a>&nbsp;(synthetic hypericin) in the treatment of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4270389-1&amp;h=4183932232&amp;u=https%3A%2F%2Fwww.soligenix.com%2Four-focus%2Fcutaneous-t-cell-lymphoma%2F&amp;a=cutaneous+T-cell+lymphoma">cutaneous T-cell lymphoma</a> (CTCL). The presentations will occur at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting in Lausanne, Switzerland on October 9-11, 2024.&nbsp;Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the&nbsp;University of Pennsylvania, will present a poster with expanded preliminary results from the investigator-initiated study (RW-HPN-MF-01) she is leading at the University of Pennsylvania. Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group, will give an oral presentation on recent results from two expanded treatment studies (HPN-CTCL-02 and HPN-CTCL-04) conducted at the Rochester Skin Lymphoma Medical Group.

Soligenix to Present New Findings on HyBryte for Treating T-Cell Lymphoma at EORTC Meeting

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 33.5% to $1.66 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares rose 31.53% to $1.46. The company's market cap stands at $62.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock rose 30.98% to $1.99. The company's market cap stands at $3.5 million. </li>
<li>OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) stock increased by 20.96% to $3.52. The company's market cap stands at $73.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.84% to $0.6. The market value of their outstanding shares is at $10.3 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.26% to $0.86. The company's market cap stands at $51.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 21.5% to $1.13 during Thursday's regular session. The market value of their outstanding shares is at $1.8 million. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock declined by 17.13% to $6.34. The company's market cap stands at $257.6 million. The company's, Q1 earnings came out today. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 16.64% to $4.06. The company's market cap stands at $9.2 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 15.7% to $1.45. The market value of their outstanding shares is at $3.4 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares declined by 14.01% to $2.21. The market value of their outstanding shares is at $89.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 12.85% to $1.96. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGO

BBLG

BYSI

GCTK

OSTX

RNAZ

TNFA

TOVX

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

WHO Chief Says Assesses The Risk Of Marburg Virus Outbreak As Very High At The National Level, High At The Regional Level, And Low At The Global Level

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 53.2% to $1.9 during Thursday's pre-market session. The company's market cap stands at $2.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 22.1% to $0.12. The company's market cap stands at $11.1 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock moved upwards by 14.0% to $0.23. The market value of their outstanding shares is at $4.1 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares increased by 13.45% to $0.42. The company's market cap stands at $4.1 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares rose 12.01% to $0.99. The company's market cap stands at $2.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 10.69% to $8.9. The market value of their outstanding shares is at $11.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 16.0% to $1.21 during Thursday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 14.79% to $4.15. The market value of their outstanding shares is at $9.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares decreased by 11.59% to $0.39. The market value of their outstanding shares is at $11.4 million. </li>
<li>ALT5 Sigma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>) stock declined by 11.3% to $1.58. The market value of their outstanding shares is at $21.3 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock decreased by 9.63% to $4.44. The company's market cap stands at $4.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock decreased by 9.08% to $17.23. The company's market cap stands at $3.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTS

BPTH

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KTTA

KZIA

NDRA

RDHL

SYRA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Soligenix and Sterling are currently working to transfer and optimize the manufacturing processes and analytics to enable GMP manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Establishes Partnership Agreement With Sterling Pharma Solutions To Optimize, Implement A Commercially Viable, Scalable Production Technology For Synthetic Hypericin

Soligenix (SNGX) announced that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin"...

Soligenix granted Hong Kong patent for production of synthetic hypericin

"We remain focused on multiple clinical activities and upcoming milestones, including the initiation of our confirmatory Phase 3 placebo-controlled...

Soligenix reports Q3 EPS (78c) vs. ($2.56) last year

Soligenix GAAP EPS of -$0.78 beats by $0.61

Soligenix (SNGX) has opened patient enrollment for its Phase 2 study evaluating SGX945 – dusquetide – in the treatment of Behcet's Disease. Soligen...

Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet's Disease

Soligenix (SNGX) announced the formation of a European Medical Advisory Board to provide additional medical/clinical strategic guidance to the comp...

Soligenix forms European Medical Advisory Board

Soligenix (SNGX) announced that analysis of the post-treatment data from the open-label study, protocol HPN-CTCL-04, comparing HyBryte to Valchlor ...

Soligenix announces analysis from protocol HPN-CTCL-04

Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneou...

Soligenix initiates confirmatory Phase 3 trial of HyBryte

Soligenix (SNGX) announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – tr...

Soligenix's HyBryte shows efficacy in T-cell lymphoma trial

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

ANIX

AZTR

BDTX

ERNA

EVAX

GBIO

GTBP

IBIO

KROS

LEXX

PHIO

RGNX

SLRX

SLXN

Screenshot 2025-01-16 at 7.00.06 PM

Soligenix Targets Psoriasis With New Therapy

Screenshot 2024-12-16 at 6.43.37 PM

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

Screenshot 2024-11-26 at 8.32.36 PM

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs

Small Cap

Press Releases

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Comments

Soligenix

Soligenix (SNGX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル